组织因子通路抑制剂2:当前的理解,挑战和未来的前景
Hiroshi Kobayashi1,2, Sho Matsubara2,3, Chiharu Yoshimoto2,4
1Department of Gynecology and Reproductive Medicine, Ms.Clinic MayOne, Kashihara, Japan.
The journal of obstetrics and gynaecology research
|August 7, 2023
概括
组织因子通路抑制剂2 (TFPI2) 在怀孕和癌症中表现出不同水平. 它作为瘤抑制剂的作用和与血栓形成的潜在联系需要进一步标准化才能进行可靠的研究.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 生殖医学 生殖医学
背景情况:
- 组织因子通路抑制剂2 (TFPI2) 在结构上与TFPI1.1相似.
- 一种来自胎盘的蛋白质TFPI2具有与妊娠并发症相关的动态变化.
- TFPI2正在成为卵巢癌的潜在血清生物标志物,特别是清细胞癌 (CCC).
研究的目的:
- 审查TFPI的生物功能2.2.
- 确定TFPI2研究当前的挑战.
- 讨论TFPI的未来研究方向2.2.
主要方法:
- 对2023年3月31日之前发表的论文进行文献综述.
- 包括来自PubMed和谷歌学者数据库的研究.
- 综合现有知识与关于TFPI2行动的新增补充信息.
主要成果:
- 孕妇,妊娠前和癌症患者的TFPI2度变化突显了其病理生理学意义.
- 通过高甲基化降低TFPI2的调节可能会促进癌症的进展;相反,CCC中的TFPI2过度表达与血栓形成风险有关.
- 关于TFPI2的生物功能存在显著差异,需要进一步调查.
结论:
- 总结了目前对TFPI2的理解,强调了现有的知识差距.
- 突出了TFPI2研究的挑战,包括缺乏标准化量化方法.
- 未来的研究应该集中于澄清TFPI2的作用和建立标准化的测量技术.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Extrinsic and Intrinsic Pathways of Hemostasis
8.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.3K


